Bruno Halpern
Overview
Explore the profile of Bruno Halpern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Artime E, Khare S, Zimner-Rapuch S, Redig J, Flannery C, Higgins V, et al.
SAGE Open Med
. 2025 Jan;
13:20503121241313082.
PMID: 39871849
Objectives: To explore the impact of obesity on clinical outcomes, health-related quality of life, emotional well-being, and work productivity in people/patients with obesity across six countries by body mass index...
2.
Moreira R, Valerio C, Hohl A, Moulin C, Moura F, Trujilho F, et al.
Arch Endocrinol Metab
. 2024 Dec;
68():e240422.
PMID: 39664998
Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable...
3.
Jastreboff A, le Roux C, Stefanski A, Aronne L, Halpern B, Wharton S, et al.
N Engl J Med
. 2024 Nov;
392(10):958-971.
PMID: 39536238
Background: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide...
4.
Dijkhorst P, de Vries C, Terwee C, Janssen I, Liem R, van Wagensveld B, et al.
Obes Rev
. 2024 Oct;
26(2):e13849.
PMID: 39419653
The lack of standardization in patient-reported outcome measures (PROMs) has made measurement and comparison of quality of life (QoL) outcomes in research focused on obesity treatment challenging. This study reports...
5.
Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care
Dijkhorst P, Monpellier V, Terwee C, Liem R, van Wagensveld B, Janssen I, et al.
Obes Surg
. 2024 Jul;
34(8):2980-2990.
PMID: 39008218
Purpose: The focus of measuring success in obesity treatment is shifting from weight loss to patients' health and quality of life. The objective of this study was to select a...
6.
Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G, et al.
Nat Med
. 2024 Feb;
30(6):1784.
PMID: 38409593
No abstract available.
7.
Coutinho W, Halpern B
Diabetol Metab Syndr
. 2024 Jan;
16(1):6.
PMID: 38172940
Obesity is a chronic, recurring, progressive disease and a major public health problem associated with several other diseases that lead to disability, morbidity, and mortality. The prevalence of obesity has...
8.
Moreira R, Valerio C, Villela-Nogueira C, Cercato C, Gerchman F, Lottenberg A, et al.
Arch Endocrinol Metab
. 2023 Dec;
67(6):e230123.
PMID: 38048417
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In...
9.
Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G, et al.
Nat Med
. 2023 Oct;
29(11):2909-2918.
PMID: 37840095
The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown. This double-blind, placebo-controlled trial randomized (1:1) adults...
10.
Halpern B, Mancini M, van de Sande-Lee S, Miranda P
Arch Endocrinol Metab
. 2023 Aug;
67(4):e230174.
PMID: 37585688
Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term "weight loss drugs" to refer to medications for the...